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Background: Eosinophilia is common in premature infants, though its clinical sig-
nificance remains unknown. This study investigated the pattern of eosinophilia and 
related factors in very low birth-weight (VLBW) infants.
Methods: The medical records of VLBW infants (birth body weight < 1500 g) admitted 
to the neonatal intensive care unit of a tertiary care center of Cheng Kung University 
Hospital between January 2005 and June 2007 were analyzed. Complete blood counts 
(CBC) with differential leukocyte counts were performed weekly. Eosinophilia was 
defined as an eosinophil count of more than 0.700 × 109/L. The possible related factors 
were analyzed.
Results: A total of 142 infants were recruited into the study. Those who did not survive 
after the first 28 days and those with less than four available CBCs were excluded, 
leaving 107 infants and 828 CBC measurements. Overall, 19.0% of CBCs (157/828) 
indicated eosinophilia and 69.0% of all infants had at least one instance of eosino-
philia during their hospital stay. Eosinophilia mainly occurred in the third week of 
life (27.1%), with an average peak eosinophil count of 0.520 × 109/L. There were 37.3% 
of patients with mild eosinophilia (0.700−0.999 × 109/L), 50.7% with moderate eosi-
nophilia (1.000−2.999 × 109/L), and 12% with severe eosinophilia (≥ 3.000 × 109/L). The 
demographic data and perinatal characteristics of infants with and without eosinophilia 
were comparable. Medical treatments including mechanical ventilation, antibiotic 
administration, total parenteral nutrition, intravenous catheterization, transfusion, 
and body weight gains were similar between the two groups. The eosinophil counts 
in the first week of life were significantly higher in infants with bronchopulmonary 
dysplasia (p < 0.05). They were also greater in VLBW infants with sepsis at the first, 
the third, the fourth, the fifth and the seventh weeks (p < 0.05).
Conclusion: Eosinophilia is common in VLBW infants and occurs mainly in the third 
week of life. Higher eosinophil counts were associated with sepsis and family history 
of atopic eczema. Bronchopulmonary dysplasia was associated with higher eosinophil 
counts in the first week of life.
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1.  Introduction
The incidence of eosinophilia in newborn infants 
ranges from 14−76%.1−5 Eosinophilia is a common find-
ing in premature infants during the neonatal period, 
and its incidence increases with imma turity.1,5 The 
incidence in premature infants with gestational ages 
less than 27 weeks is as high as 75%.1 The reasons for 
the high incidence of eosinophilia are unknown.
Eosinophils normally account for only 1−3% of 
peripheral blood leukocytes. In neonates, eosin ophilia 
is defined as an eosinophil count of more than or 
equal to 0.700 × 109/L, and has been further sub-
classified as mild (0.700−0.999 × 109/L), moderate 
(1.000−2.999 × 109/L), or severe (> 3.000 × 109/L).1,3,6
Previous studies have reported eosinophilia in 
association with numerous conditions, such as the 
establishment of an anabolic state, drug reactions, 
response to foreign antigens, chronic lung disease, 
erythropoietin treatment, total parenteral nutrition 
(TPN), and infections.1,3,4,7 However, its clinical sig-
nificance in premature infants has yet to be deter-
mined. Previous studies have not emphasized very 
low birth-weight (VLBW) infants. Medical care of 
such premature infants varies greatly and can lead to 
bias in these studies. Our understanding of the sig-
nificance of eosinophilia in these infants will be im-
proved by studies that distinguish VLBW infants from 
other premature infants.
Eosinophilia has been proven to be related to the 
development of allergies; a family history of allergic 
disease is the major determining factor.8−11 There-
fore, the relationship between eosinophilia in early 
life and family history of allergy deserves further 
investigation.11−13
A number of hypotheses have been proposed to 
explain the causes of eosinophilia in prematurity.1,2,5,6 
Eosinophilia frequently occurs in severely sick pre-
mature infants, especially in those developing bron-
chopulmonary dysplasia (BPD).2−4 However the clinical 
significance of eosinophilia in premature infants 
remains unknown. We hypothesized that more pre-
mature infants would be at greater risk for eo-
sinophilia. We therefore aimed to investigate the 
incidence and pattern of eosinophilia and the fac-
tors associated with it in VLBW infants. Differences 
in the time courses, incidences, and severity of eo-
sinophilia in VLBW infants were evaluated with re-
spect to their different clinical conditions.
2.  Materials and Methods
The medical records of VLBW infants (birth body 
weight < 1500 g) admitted to the neonatal intensive 
care unit (NICU) of a tertiary care center between 
January 2005 and June 2007 were analyzed. The 
following exclusion criteria were used: (1) infants 
who failed to survive the first 28 days; (2) infants with 
less than four complete blood counts (CBC); and (3) 
infants admitted to the NICU after 2 weeks of age.
We collected CBC data with differential leuko-
cyte counts weekly for 8 weeks. In the case of an 
infection, CBC data and blood cultures were collected 
simultaneously. A possible association between eo-
sinophilia and packed red blood cell (PRBC) transfu-
sion was evaluated during the 7-day period following 
a PRBC transfusion.
Eosinophilia was defined as an eosinophil count 
of 0.700 × 109/L or more, and was further subclas-
sified into mild (0.700−0.999 × 109/L), moderate 
(1.000−2.999 × 109/L), and severe (> 3.000 × 109/L) 
eosinophilia.1,2 High eosinophil percentage was de-
fined as eosinophils above 6% of total white blood 
cell (WBC) differential count. We defined neutrope-
nia as absolute neutrophil count (ANC) of less than 
1.100 × 109/L, and neutrophilia as ANC > 15.000 × 
109/L in the first 60 hours of life or ANC above 
6.000 × 109/L thereafter, in accordance with the 
stringent definition of the VLBW population char-
acterized by Mouzinho’s study.14 A WBC count of 
more than 35,000 was used to define leukocytosis, 
according the cutoff value of Hill and Duncan.15
Data on maternal history, delivery process and 
postnatal course were retrieved from the medical 
records of the VLBW infants. Gestational age, birth 
weight, Apgar scores, weekly weight gain, and med-
ical treatments such as mechanical ventilation, 
antibiotic administration, TPN, intravenous cathe-
terization, transfusion, and clinical diagnoses were 
also documented.
The diagnosis of sepsis was based on clinical 
signs suggesting infection, such as recurrent apnea 
(three episodes within 24 hours), bradycardia, un-
stable body temperature, clinical deterioration, 
elevated C-reactive protein, and on positive blood 
culture results.1,16
BPD was diagnosed according to the clinical and 
radiographic features defined by National Institute 
of Child Health and Human Development.17,18
(1)  Mild BPD: Treatment with oxygen > 21% for at 
least 28 days plus breathing of room air till 36-
week postmenstrual age (PMA) or discharge, 
whichever comes first;
(2)  Moderate BPD: Treatment with oxygen > 21% 
for at least 28 days, plus need for < 30% oxygen 
till 36-week PMA or discharge, whichever comes 
first;
(3)  Severe BPD: Treatment with oxygen > 21% for 
at least 28 days, plus need for < 30% oxygen 
and/or positive pressure, (positive-pressure 
ventilation or nasal continuous positive airway 
pressure) till 36-week PMA or discharge, which-
ever comes first.
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A family history of allergy was determined by 
telephone interviews performed by the case man-
ager. Infants were considered to have a family his-
tory of allergy if there were clinical symptoms or 
a verified diagnosis of asthma, allergic rhinitis, al-
lergic eczema or drug allergy in their parents, sib-
lings or relatives.9,12,13
The study was approved by the Institutional 
Review Board of the National Cheng Kung University 
Hospital. Informed consent was obtained from the 
parents of all infants.
2.1.  Statistical analysis
The data were analyzed using SPSS version 13.0 
(SPSS Inc., Chicago, IL, USA). Continuous variables 
were compared among groups using unpaired Stu-
dent’s t tests or analysis of variance, and χ2 tests were 
used to compare groups with respect to categorical 
variables. Results are reported as mean ± SEM and 
p less than 0.05 was considered significant.
3.  Results
A total of 142 VLBW infants were recruited. Thirty-
five patients were excluded and 107 infants providing 
828 CBCs met the inclusion criteria. Overall, 19.0% 
of CBCs (157/828) showed eosinophilia, and 69.0% of 
infants had at least one instance of eosinophilia dur-
ing their hospital stay. Eosinophilia mainly occurred 
in the third week of life (27.1%) with an average peak 
eosinophil count of 0.520 × 109/L (Figures 1 and 2). 
There were 37.3% of infants with mild eosinophilia, 
50.7% with moderate eosinophilia, and 12% with se-
vere eosinophilia (Figure 3).
Figure 1 The incidence of eosinophilia peaked in the 
third week and declined after the fifth week.
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Figure 2 Change in eosinophil counts over the 8-week 
period. Eosinophil counts increased after birth, reached a 
peak in the third week and remained around 0.400 × 109/L 
during the observation period (error bars, 95% CI).
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Figure 3 Incidence and severity of eosinophilia in very 
low birth-weight infants.
12.0% severe eosinophilia
(> 3.000 × 109/L)
50.67% moderate eosinophilia
(1.000 − 2.999 × 109/L)
37.33% mild eosinophilia
(0.700 − 0.999 × 109/L)
Table 1 shows the demographic data and peri-
natal characteristics of the infants with or without 
eosinophilia. There were no significant differences 
between the two groups with regard to any of these 
variables. Table 2 shows the CBC data with differen-
tial counts, absolute eosinophil counts and eosinophil 
percentages in infants with or without eosinophilia. 
Eosinophil count and eosinophil percentage were 
significantly correlated with WBC count only in the 
first week (p = 0.5), but not in later weeks. Further, 
the eosinophil counts in the eosinophilia group were 
significantly correlated with eosinophil percent-
age, while WBC counts were not. Table 3 shows no 
differences in the incidences of respiratory distress 
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Table 1  Demographic data and perinatal character-
istics of infants with or without eosinophilia*
 With Without 
 eosinophilia eosinophilia
Infants† 74 (69.2) 33 (30.8)
Female† 49 (66.2) 21 (63.6)
GA (wk)† 28.08 ± 2.76 28.79 ± 2.631
BBW (g)† 1028 ± 246 1081 ± 253
Maternal age (yr)† 30.3 ± 4.0 30.5 ± 5.5
Apgar score
  1 min (mode, range) 6 (0−8) 6 (1−9)
  5 min (mode, range) 8 (0−10)  9 (5−10)
Inborn† 51 (68.9) 23 (69.7)
CRIB score 1 (0−14) 1 (0−11)
 (mode, range)
NTISS score 21 (9−33) 9 (7−31)
 (mode, range)
Perinatalx steroid 61 (82.4) 25 (75.8)
 used (%)†
*Eosinophil count ≥ 0.700 × 109/L is considered eosinophilia; 
†values expressed as n (%) or mean ± SD. GA = gestational 
age; BBW = birth body weight; CRIB = Clinical Risk Index for 
Babies; NTISS = Neonatal Therapeutic Intervention Scoring 
System.
syndrome, patent ductus arteriosus, necrotizing en-
terocolitis (NEC), intraventricular hemorrhage or 
retinopathy of prematurity between the two groups. 
Medical treatments such as prenatal steroid, me-
chanical ventilation, antibiotics, TPN, percutaneous 
central venous catheterization, transfusion, feed-
ing formula, body weight gain, postnatal steroids, 
and prophylactic fluconazole were not associated 
with eosinophilia.
Table 4 shows no significant differences between 
the two groups in terms of allergic family history 
of asthma, allergic rhinitis or drug allergies. How-
ever, the eosinophil counts were significantly higher 
in infants with a family history of atopic eczema 
(p < 0.01).
Figure 4 shows that WBC counts and neutrophil 
counts gradually decreased after birth and became 
stable at the fifth week of life. Overall, neutropenia 
occurred in 27 (25.2%) infants and in 5.8% of the total 
CBC data. Neutrophilia occurred in 82 (70.3%) infants 
and in 18.5% of the total CBC data in our study. 
Eosinophil counts changed less noticeably, in com-
parison to the WBC and neutrophil counts. WBC 
counts and neutrophil counts were significantly 
correlated throughout the whole observation period 
(p < 0.01). Eosinophil counts showed a separate trend 
that was significantly different from those shown 
by both the WBC and neutrophil counts.
Fifty-nine percent of the infants in this study had 
BPD. Of these, 55.7% had mild BPD, 41.1% had mod-
erate BPD, and 3.3% had severe BPD. As shown in 
Figure 5, the eosinophil count in the first week of life 
was higher in infants with BPD (p < 0.05). When com-
pared to the absolute eosinophil counts (AEC) in in-
fants without BPD, AEC in the BPD group decreased 
during the second week of life and remained low until 
after the sixth week, when the AEC in this group 
became higher. The use of postnatal steroids in in-
fants with BPD was higher than in those without BPD, 
although the difference was not significant (p = 0.075). 
The period of steroid use was between 14th and 82nd 
of life, and 60% of use occurred between 25th and 39th 
of life.
The effects of infection on eosinophil counts 
were evaluated, as shown in Figure 6. Fifty-four 
infants had sepsis, of which 75.8% had eosinophilia. 
Among all infants with infection, only 24.2% were 
without eosinophilia, 24.2% had mild eosinophilia, 
40.3% had moderate eosinophilia and 11.3% had se-
vere eosinophilia. The eosinophil counts in VLBW in-
fants with sepsis were higher than in those without 
during the first (positive blood culture: 11 cases), 
third (18 cases), fourth (13 cases), fifth (8 cases) 
and seventh (8 cases) weeks (p < 0.05). However, the 
eosinophil counts were similar in VLBW infants with 
and without sepsis during the second (positive blood 
culture: 7 cases), sixth (3 cases) and eighth (4 cases) 
weeks of postnatal age. 
4.  Discussion
In this retrospective study, 69% of all infants had at 
least one instance of eosinophilia during their hos-
pital stay. Its peak incidence occurred in the third 
week of life. The degree of eosinophilia was mild 
in 37.3% (0.700−0.999 × 109/L), moderate in 50.7% 
(1.000−2.999 × 109/L), and severe in 12% (≥ 3.000 × 
109/L). The WBC counts and ANC climaxed after 
birth, then gradually decreased and became stable 
after the fifth week of life. The eosinophil count was 
significantly higher in infants with BPD during their 
first week of life. Higher eosinophil counts were 
associated with sepsis.
The results of this study showed an inverse rela-
tionship between the incidence of eosinophilia and 
gestational age, as found in earlier studies.1,4,5 The 
incidence of eosinophilia in this study was similar to 
those in other studies of infants of similar gestational 
ages.1 The current study revealed that the elevated 
eosinophil count was correlated with the eosinophil 
percentage, and not with an elevation of WBC count, 
in patients with eosinophilia. This represented a 
significant difference between the eosinophilia 
and non-eosinophilia groups. Pre vious reports have 
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suggested that eosinophilia may be associated with 
numerous conditions such as the establishment of an 
anabolic state, drug reactions, and response to for-
eign antigens.19−22 However, no specific conditions 
were associated with eosinophilia in this study. This 
could be because the subjects were VLBW infants, 
and the incidences of intubation (54.9%) and paren-
teral nutrition (89%) were therefore high.
Both reports by Mouzinho et al14 and the current 
study revealed that initial high WBC counts and neu-
trophil counts in VLBW infants decreased with in-
creasing time since birth.14,23,24 Sandra et al24 found 
that initial high WBC and neutrophil counts in infants 
under 27 weeks’ gestational age could persist for 
3 weeks, and would then decrease at the fourth week 
after birth. However, this phenomenon was not dem-
onstrated in the present study. In our study, 25.2% of 
infants and 5.8% of total CBC data revealed neutro-
penia, and 70.3% of infants and 18.5% of total CBC 
data revealed neutrophilia. Our patients appeared to 
have a lower incidence of neutropenia than those 
in this earlier study. This discrepancy could be due to 
their higher incidence of NEC (6 infants required sur-
gical treatment, and 8 required medical treatment 
with an overall mortality of 36%), contributing to 
the significant relationship with neutropenia in 
their study.24 Further investigation is needed to clar-
ify the influence of a lower incidence of NEC (17 in-
fants out of 107, 15.8%; 16 infants had NEC stage I, 3 
infants had NEC stage IIa, all infants were treated 
medically, and mortality was 0%) on the incidence 
of neutropenia. The definition of neutropenia used in 
the current study was ANC less than 1.100 × 109/L, 
which was lower than the commonly used definition 
of ANC less than 1.500 × 109/L ,24,25 and may also have 
contributed to the differences between the studies. 
It is also possible that the higher incidence of sep-
sis in our study may have contributed to the higher 
Table 2  Correlation of white blood cell counts, eosinophil count and eosinophil percentage in very low birth-
weight infants with eosinophilia*
  With eosinophilia Without eosinophilia
Week 1 Cases (n)  18 94
 WBC  26.047 ± 17.731† 15.450 ± 6.002
 Eosinophil count  2.604 ± 0.535† 0.206 ± 0.202
 Mean percentage (range) 10 (2−26)† 2.4 (0−10)
Week 2 Cases (n)  15 88
 WBC  11.713 ± 5.775 10.440 ± 5.772
 Eosinophil count  0.953 ± 0.457† 0.218 ± 0.207
 Mean percentage (range)  7.9 (5−13)† 2.2 (0−8)
Week 3 Cases (n)  29 87
 WBC  11.384 ± 3.449 9.680 ± 4.676
 Eosinophil count 1.229 ± 0.592† 0.257 ± 0.202
 Mean percentage (range) 11 (4−23)† 3 (0−11)
Week 4 Cases (n)  25 78
 WBC  10.064 ± 3.018 9.184 ± 4.852
 Eosinophil count  1.019 ± 0.352† 0.270 ± 0.202
 Mean percentage (range)  10 (5−21)† 3.6 (0−15)
Week 5 Cases (n)  27 65
 WBC  8.727 ± 3.680 9.132 ± 3.137
 Eosinophil count  1.043 ± 0.384† 0.209 ± 0.205
 Mean percentage (range)  11 (6−22)† 2.6 (0−12)
Week 6 Cases (n)  18 66
 WBC  9.372 ± 3.205 8.650 ± 3.179
 Eosinophil count 1.065 ± 0.397† 0.291 ± 0.219
 Mean percentage (range) 12 (4−22) † 3.5 (0−11)
Week 7 Case number (n)  15 57
 WBC  10.084 ± 3.215 8.182 ± 2.499
 Eosinophil count 1.152 ± 0.475† 0.270 ± 0.265
 Mean percentage (range)  12 (5−22)† 3.5 (0−19)
Week 8  Case number (n)  15 50
 WBC  9.253 ± 2.751 8.353 ± 2.367
 Eosinophil count 1.154 ± 0.385† 0.291 ± 0.230
 Mean percentage (range)  13 (7−20)† 3.8 (0−12)
*Values for WBC and eosinophil count are expressed as mean ± SD (× 109/L); †p < 0.05 where eosinophil count was significantly 
greater in the group with eosinophilia than without. WBC = white blood cell.
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Table 3  Comparison of clinical characteristics in very 
low birth-weight infants with and without 
eosinophilia*
 With Without
  eosinophilia n (%) eosinophilia n (%)
Infants 74 (69.2) 33 (30.8)
Intubation  43 (58.1) 15 (45.5)
PCVC  66 (90.4) 28 (84.4)
TPN  66 (89.2) 28 (84.8)
RDS  
  Grade 1 35 (47.3) 19 (57.6)
  Grade 2 18 (24.3) 6 (18.2)
  Grade 3 6 (8.1) 2 (6.1)
  Grade 4 5 (6.8) 2 (6.3)
PDA 31 (41.9) 15 (45.5)
IVH  
  Grade 1 7 (9.5) 2 (6.1)
  Grade 2 2 (2.7) 1 (3.0)
  Grade 3 3 (4.1) 0 (0)
  Grade 4 2 (2.7) 0 (0)
ROP   
  Grade 1 11 (14.9) 5 (15.2)
  Grade 2 11 (14.9) 3 (9.1)
  Grade 3 9 (12.2) 4 (12.1)
  Grade 4 1 (1.4) 0 (0)
Feeding   
  BM 36 (48.6) 19 (57.6)
  BM + FM 20 (27.0) 10 (30.3)
  FM 14 (18.9) 4 (12.1)
NEC   
  Stage 1 11 (17.3) 3 (9.4)
  Stage 2 3 (4) 0 (0)
  Stage 3 0 (0) 0 (0)
  Stage 4 0 (0) 0 (0)
Postnatal  20 (27.8) 4 (12.5) 
 steroid use†
Fluconazole  56 (74.7) 23 (71.9) 
 prophylaxis‡
*Eosinophil count ≥ 0.700 × 109/L is considered eosinophilia; 
†p = 0.074; ‡p = 0.764. PCVC = percutaneous central venous 
catheterization; TPN = total parenteral nutrition; RDS = res-
piratory distress syndrome; PDA = patent ductus arteriosus; 
IVH = intraventricular hemorrhage; ROP = retinopathy of pre-
maturity; BM = breast milk; FM = formula milk; NEC = necro-
tizing enterocolitis.
incidence of neutrophilia, compared with a previ-
ous study.23
Fluconazole is the drug most frequently discussed 
in association with eosinophilia.26 Current practice at 
the National Cheng Kung University Hospital is for 
preterm infants with birth weights under 1200 g to 
routinely receive prophylactic fluconazole to prevent 
fungemia and its associated morbidity and mortality. 
Therefore, 73.8% of infants received fluconazole. 
Table 4  Comparison of atopic family history in very 
low birth-weight infants with or without 
eosinophilia*
 
All
 With Without 
  eosinophilia* eosinophilia
Infants (n) 66 39 27
Asthma 5 2 3
Allergic rhinitis 38 21 17
Atopic eczema† 15 11 4
Drug allergy 16 8 8
*Eosinophil count ≥ 0.700 × 109/L is considered eosinophilia; 
†p < 0.01.
Figure 4 Average changes in white blood cell (WBC), 
neutrophil and eosinophil counts over the observation 
period. WBC and neutrophil count were significantly 
correlated throughout the whole observation period 
(p < 0.01). The pattern of changes in eosinophil counts 
differed from those in WBC and neutrophil counts.
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There was no significant difference in the incidences 
of eosinophilia between those treated with fluco-
nazole and those who were not (74.7% vs. 71.9%, 
p = 0.764). Previous studies, however, found a sig-
nificant association between fungemia and 
eosinophilia.21,26 There was one infant in the current 
study with a body weight of 1250 g who did not re-
ceive fluconazole prophylaxis and who developed 
fungemia. The incidence of eosinophilia in this study 
was not affected by reduced fungemia with pro-
phylactic use of fluconazole.
In our study, 86 infants (82.7%) received prenatal 
steroid therapy, while 18 (17.3%) did not. There were 
no significant differences between these two groups 
in terms of WBC counts, eosinophil counts, or eosi-
nophil percentages. A similar result was found in a 
cohort study conducted by Morag et al27 in 196 VLBW 
infants. Calhoun et al,28 in a study of bone marrow 
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samples from VLBW infants born at under 30 weeks’ 
gestational age, revealed an increased production of 
neutrophils from the bone marrow, suggesting a ki-
netic mechanism in the bone marrow as the main 
cause of leukocytosis, rather than a corticosteroid-
induced mechanism.
Previous studies have shown eosinophilia to be 
associated with infection.1,9,18,21,22 In this study, 50.5% 
Figure 5 Peripheral eosinophil counts in very low birth-
weight infants without and with bronchopulmonary dys-
plasia (BPD). They were only significantly different in 
the first week of life. Eosinophil counts were lower in 
infants with BPD but not significantly different between 
the two groups in the second, third, fourth and fifth 
weeks of life. *p < 0.05.
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Figure 6 Effect of sepsis on eosinophil counts. Eosinophil 
counts in very low birth-weight infants with sepsis were 
higher than those without sepsis at the first, third, fourth, 
fifth and seventh weeks (p < 0.05). However, the eosinophil 
counts were similar during the second, sixth and eighth 
weeks of postnatal age. *p < 0.05.
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of these VLBW infants had infections during the pe-
riod of admission, and 78% of these had eosinophilia. 
The eosinophil count was significantly higher in cases 
with sepsis, in accordance with results from previous 
studies.1,9,20,22,26 Eosinophil granules contain eosi-
nophil cationic protein, eosinophil peroxidase, and 
eosinophil-derived neurotoxin, as well as various 
cytokines and lipid mediators generated after cel-
lular activation. Eosinophils thus produce unique 
toxic inflammatory mediators and perform a char-
acteristic role in the process of infec tion.1,29−31 
Eosinophilia may be harmful because of the proin-
flammatory effects of eosinophils and destruction of 
tissue,7,10,31 which could explain why the eosinophil 
count was significantly higher in patients with sepsis 
in our study. The absence of any relationship be-
tween sepsis and eosinophilia in the second, sixth 
and eighth weeks of life could be due to the fact 
that the majority of the infants received at least 
3 days of prophylactic antibiotics in their first week 
of admission to the NICU, which might have de-
creased the incidence of sepsis at the second week 
(only 6 blood culture-positive cases in the second 
week). The differences during the sixth and eighth 
weeks of life were not significant, possibly because 
there were very few culture-proven cases, only four 
and three cases, respectively. The eosinophil count 
and WBC count were significantly greater in the 
sepsis group than those of the non-sepsis group (at 2, 
6 and 8 weeks). Meanwhile, the eosinophil percent-
age was not correlated with eo sinophil count in 
patients with sepsis, suggesting an overwhelming 
leukocytosis in sepsis that blurred the correlation 
between eosinophil count and its percentage. These 
results suggest that WBC alone is inadequate for di-
agnosing clinical infection; eosinophil count and per-
centage are also important measures for the diagnosis 
of clinical infection in non-septic VLBW infants.
Survival of VLBW infants has improved signifi-
cantly over recent decades, but the incidence of 
BPD remains high and BPD is still regarded as a major 
cause of morbidity.17,32 Previous studies have re-
ported controversial results regarding the relation-
ship between BPD and eosinophilia.3−5 In this study, 
we found that the eosinophil count was signifi-
cantly higher in infants with BPD during their first 
week of life (p < 0.05), after which the eosinophil 
counts decreased at the third, fourth and fifth 
weeks of life compared to those of the infants 
without BPD. Postnatal steroids were used to wean 
ventilator-dependent infants. However, no signifi-
cant effect of steroid treatment was observed in 
these cases (p = 0.075). Twenty infants with BPD 
were given postnatal steroids between days 14 and 
82. Sixty percent of these infants received steroids 
between the 20th and 39th of life. It is possible that 
the lack of any significant relationship may have 
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been due to the small number of cases (there were 
only four cases who received postnatal steroids 
but were without eosinophilia). Previous studies, 
however, found that the use of steroids was associ-
ated with a decreased eosinophil count.7,27
Approximately 71% of the infants (71/107) re-
ceived PRBC transfusions in the current study. There 
was no relationship between the weekly eosinophil 
count and PRBC transfusion 1 week before, or be-
tween eosinophilia and transfusion of PRBC as a 
whole.1,19,20
In contrast to earlier studies that revealed an as-
sociation between eosinophilia and positive weight 
gain,33 we found no correlation between recorded 
body weight gain and eosinophil count in the present 
study. However, infants in the present study did not 
vary significantly in terms of their birth weights, in 
contrast to other study populations which showed 
diverse birth weights. This could account for the 
significant differences detected in their studies.
In conclusion, there was a high incidence of 
eosinophilia in VLBW infants in our investigation. 
The peak eosinophil count occurred during the 
third week of life. The WBC counts and ANC climaxed 
after birth, then gradually decreased and became 
stable at the fifth week of life. Higher eosinophil 
counts were significantly associated with sepsis and 
a family history of atopic eczema. Infants with BPD 
also had higher eosinophil counts in their first week 
of life.
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